{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:56:01Z","timestamp":1771264561314,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.thromres.2016.08.008","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T05:54:53Z","timestamp":1470894893000},"page":"119-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Cost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma"],"prefix":"10.1016","volume":"145","author":[{"given":"Emilie","family":"Chalayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Bourmaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Tinquaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Chauvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Tardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2016.08.008_bb0005","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.08.008_bb0010","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2016.08.008_bb0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.thromres.2016.08.008_bb0020","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2016.08.008_bb0025","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","article-title":"Thrombosis is associated with inferior survival in multiple myeloma","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2016.08.008_bb0030","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Carrier","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.08.008_bb0035","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/cncr.26302","article-title":"Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis","volume":"118","author":"Anaissie","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2016.08.008_bb0040","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1200\/JOP.2015.004473","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"11","author":"Lyman","year":"2015","journal-title":"J. Oncol. Pract. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.thromres.2016.08.008_bb0045","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.thromres.2016.08.008_bb0050","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2013.099358","article-title":"European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma","volume":"99","author":"Engelhardt","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2016.08.008_bb0060","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2016.08.008_bb0065","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0609.2004.00346.x","article-title":"Health related quality of life in patients with multiple myeloma undergoing a double transplantation","volume":"74","author":"Uyl-de Groot","year":"2005","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.thromres.2016.08.008_bb0070","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2016.08.008_bb0075","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.thromres.2016.08.008_bb0080","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","article-title":"Incidence and mortality of venous thrombosis: a population-based study","volume":"5","author":"Naess","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.08.008_bb0085","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/bjs.9579","article-title":"Outcome and complications after intra-arterial thrombolysis for lower limb ischaemia with or without continuous heparin infusion","volume":"101","author":"Grip","year":"2014","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.thromres.2016.08.008_bb0090","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(13)62070-X","article-title":"Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK","volume":"383","author":"Chung","year":"2014","journal-title":"Lancet. Lond. Engl."},{"key":"10.1016\/j.thromres.2016.08.008_bb0095","first-page":"1071","article-title":"Epidemiology of stroke in northern Italy: the Cerebrovascular Aosta Registry, 2004-2008","volume":"34","author":"Corso","year":"2013","journal-title":"Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol."},{"key":"10.1016\/j.thromres.2016.08.008_bb0100","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/1472-6963-12-392","article-title":"Defining upper gastrointestinal bleeding from linked primary and secondary care data and the effect on occurrence and 28day mortality","volume":"12","author":"Crooks","year":"2012","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.thromres.2016.08.008_bb0105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0002-9343(01)00793-8","article-title":"Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis","volume":"111","author":"Marchetti","year":"2001","journal-title":"Am. J. Med."},{"key":"10.1016\/j.thromres.2016.08.008_bb0110","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/0272989X0002000403","article-title":"Patient preference-based treatment thresholds and recommendations: a comparison of decision-analytic modeling with the probability-tradeoff technique","volume":"20","author":"Man-Son-Hing","year":"2000","journal-title":"Med. Decis. Mak."},{"key":"10.1016\/j.thromres.2016.08.008_bb0120","first-page":"1","article-title":"The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation","volume":"15","author":"Picot","year":"2011","journal-title":"Health Technol. Assess. Winch. Engl."},{"key":"10.1016\/j.thromres.2016.08.008_bb0125","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1160\/TH04-11-0767","article-title":"Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism","volume":"93","author":"Aujesky","year":"2005","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.08.008_bb0130","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1378\/chest.11-0625","article-title":"Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis","volume":"141","author":"Blondon","year":"2012","journal-title":"Chest J."},{"key":"10.1016\/j.thromres.2016.08.008_bb0135","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.jvs.2009.12.070","article-title":"National trends in venous disease","volume":"51","author":"Barnes","year":"2010","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.thromres.2016.08.008_bb0140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00228-010-0956-5","article-title":"Drug use problems with self-injected low-molecular-weight heparins in primary care","volume":"67","author":"Mengiardi","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.thromres.2016.08.008_bb0145","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/j.1538-7836.2010.03901.x","article-title":"Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies: letters to the editor","volume":"8","author":"Verso","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.08.008_bb0150","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1182\/blood-2002-06-1674","article-title":"Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy","volume":"100","author":"Cavo","year":"2002","journal-title":"Blood"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384816305084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384816305084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T08:14:46Z","timestamp":1568276086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384816305084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":28,"alternative-id":["S0049384816305084"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2016.08.008","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2016.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}